GSG Advisors LLC Decreases Stock Holdings in CorMedix Inc. (NASDAQ:CRMD)

GSG Advisors LLC reduced its holdings in shares of CorMedix Inc. (NASDAQ:CRMDFree Report) by 24.2% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 37,500 shares of the company’s stock after selling 12,000 shares during the quarter. GSG Advisors LLC owned 0.07% of CorMedix worth $155,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of the business. Tower Research Capital LLC TRC boosted its stake in shares of CorMedix by 325.5% in the fourth quarter. Tower Research Capital LLC TRC now owns 13,981 shares of the company’s stock valued at $53,000 after purchasing an additional 10,695 shares during the period. Beacon Pointe Advisors LLC purchased a new position in shares of CorMedix in the fourth quarter valued at $90,000. MJP Associates Inc. ADV purchased a new position in shares of CorMedix in the fourth quarter valued at $94,000. SG Americas Securities LLC purchased a new position in shares of CorMedix in the fourth quarter valued at $107,000. Finally, Advisor OS LLC boosted its stake in shares of CorMedix by 20.0% in the fourth quarter. Advisor OS LLC now owns 30,000 shares of the company’s stock valued at $113,000 after purchasing an additional 5,000 shares during the period. 34.18% of the stock is currently owned by hedge funds and other institutional investors.

CorMedix Trading Down 0.9 %

CRMD stock traded down $0.04 during mid-day trading on Friday, hitting $4.39. 519,171 shares of the company were exchanged, compared to its average volume of 430,501. The company has a market capitalization of $241.27 million, a PE ratio of -4.72 and a beta of 1.73. CorMedix Inc. has a twelve month low of $2.57 and a twelve month high of $7.00. The firm has a fifty day simple moving average of $5.19 and a 200 day simple moving average of $4.19.

CorMedix (NASDAQ:CRMDGet Free Report) last announced its quarterly earnings data on Thursday, May 9th. The company reported ($0.25) earnings per share for the quarter, topping the consensus estimate of ($0.27) by $0.02. As a group, sell-side analysts anticipate that CorMedix Inc. will post -0.85 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on the stock. JMP Securities restated a “market outperform” rating and issued a $19.00 target price on shares of CorMedix in a research note on Tuesday, April 9th. Needham & Company LLC reissued a “buy” rating and set a $10.00 price objective on shares of CorMedix in a report on Wednesday. Finally, Royal Bank of Canada decreased their price objective on shares of CorMedix from $10.00 to $9.00 and set an “outperform” rating for the company in a report on Wednesday, March 13th.

Get Our Latest Stock Analysis on CorMedix

About CorMedix

(Free Report)

CorMedix Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure.

Featured Stories

Want to see what other hedge funds are holding CRMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CorMedix Inc. (NASDAQ:CRMDFree Report).

Institutional Ownership by Quarter for CorMedix (NASDAQ:CRMD)

Receive News & Ratings for CorMedix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CorMedix and related companies with MarketBeat.com's FREE daily email newsletter.